30 August 2024
ECO Animal Health Group plc
("ECO" or the "Company")
Director/PDMR Dealings
ECO Animal Health Group plc, a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has been notified that on 30 August 2024, David Hallas, Chief Executive Officer, purchased 18,181 ordinary shares of 5 pence each ("Ordinary Shares") at a price of 110 pence per share.
Following this transaction, David Hallas' total interest in the Company is 109,334 Ordinary Shares, representing approximately 0.16 per cent. of the Company's issued share capital.
Details of the transactions can be found in the Notification of Dealing Form below.
For further information please contact:
| ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO) |
|
| Singer Capital Markets (Nominated Adviser & Joint Broker) Phil Davies Sam Butcher | 020 7496 3000 |
| Investec (Joint Broker) Gary Clarence Lydia Zychowska | 020 7597 5970
|
| Equity Development Hannah Crowe Matt Evans | 020 7065 2692 |
| ICR Consilium (Financial PR) Mary-Jane Elliott Jessica Hodgson | 020 3709 5700 ecoanimalhealth@consilium-comms.com
|
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
| a)
| Name
| David Hallas | |||
| 2
| Reason for the notification
| ||||
| a)
| Position/status
| Chief Executive Officer | |||
| b)
| Initial notification /Amendment
| Initial notification | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
| a)
| Name
| ECO Animal Health Group plc | |||
| b)
| LEI
| 2138009XN9DJ3YP70B55 | |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
| a)
| Description of the financial instrument, type of instrument | Ordinary shares of 5 pence each
| |||
| | | ||||
| Identification code | GB0032036807 | ||||
| | | ||||
| b)
| Nature of the transaction
| Purchase of Ordinary Shares | |||
| c)
| Price(s) and volume(s) | | | | |
| | | Price(s) | Volume(s) | | |
| | | 110 pence
| 18,181 | | |
| | | | | | |
| d)
| Aggregated information | N/A - Single transaction | |||
| | | ||||
| - Aggregated volume | | ||||
| | | ||||
| - Price | | ||||
| | | ||||
| e)
| Date of the transaction
| 30 August 2024
| |||
| f)
| Place of the transaction
| London Stock Exchange, AIM | |||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.